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Abstract Environmental factors and endogenously pro-
duced toxins, such as 1-benzyl-1,2,3,4-tetrahydroisoquin-
oline (1BnTIQ), are considered to be involved in the
pathogenesis of Parkinson’s disease (PD). In this study, we
investigated the impact of single and multiple 1BnTIQ (25
and 50 mg/kg i.p.) administration on L-DOPA-induced
changes in the rate of dopamine and serotonin metabolism
in the rat brain. Additionally, using in vivo microdialysis,
we measured the impact of acute and multiple 1BnTIQ
administrations on L-DOPA-induced dopamine release in
the striatum. These data were compared with results from
behavioral tests in which we measured the effect of
1BnTIQ and L-DOPA on locomotor activity. Finally, we
determined the effect of the repeated administration of
1BnTIQ on the L-DOPA-induced elevation of caspase-3
activity in the hippocampus. An ex vivo neurochemical
study indicated that both acute and chronic 1BnTIQ
injections strongly inhibited L-DOPA-induced increases in
the concentration of dopamine and all of its metabolites in
dopaminergic structures. In contrast, in vivo microdialysis
studies suggested that the differences in 1BnTIQ’s effects
are dependent on the type of treatment. A single dose of
1BnTIQ intensified the elevation of dopamine release
induced by L-DOPA administration (*1,300 %;
P \ 0.01), while multiple administrations of 1BnTIQ sig-
nificantly enhanced the basal dopamine levels while
partially diminishing the effects of L-DOPA injection
(*200 %; P \ 0.01). Additionally, we found that chronic
administration of 1BnTIQ completely blocked the
L-DOPA-induced increase in caspase-3 activity in the
hippocampus. These findings indicate that both acute and
chronic administrations of 1BnTIQ disturbs the behavioral
and biochemical effects of L-DOPA in the rat. The data
presented from ex vivo and in vivo studies clearly suggest
that 1BnTIQ’s effects may be connected with the inhibition
of DAT and/or COMT activity in the brain. Furthermore,
elevated endogenous levels of 1BnTIQ may pose a serious
risk in PD patients undergoing L-DOPA therapy.
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Introduction
Parkinson’s disease (PD) is an age-related movement dis-
order characterized by a progressive loss of dopaminergic
neurons of the substantia nigra and is associated with
postural and behavioral abnormalities, such as bradykine-
sia, tremors, and rigidity (Klockgether 2004). In spite of
intensive research efforts, the cause of dopaminergic cell
neurodegeneration in PD remains unknown. Some factors
that may be responsible for the degeneration of dopami-
nergic neurons are oxidative stress, mitochondrial dys-
function, protein misfolding, apoptosis, and inflammation
(Gandhi and Wood 2005; Moore et al. 2005; Sas et al.
2007). Dopaminergic brain structures are particularly sen-
sitive to oxidative stress because the metabolism of dopa-
mine itself leads to the generation of reactive oxygen
species (ROS). ROS initiate the mitochondrial-caspase
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cascade, which leads to the activation of the main effector,
caspase-3 (Hanrott et al. 2006; Bayir et al. 2009). Cur-
rently, L-DOPA is the best treatment available for
improving the symptoms of PD. L-DOPA therapy is
required by all PD patients at some stage in their illness.
The pathogenesis of PD may involve both environ-
mental factors and endogenous toxins. 1-Benzyl-1,2,3,
4-tetrahydroisoquinoline (1BnTIQ), an endogenous
neurotoxin, has been proposed as a possible etiological
factor of idiopathic PD (Kotake et al. 1995). The con-
centration of 1BnTIQ in the CSF of parkinsonian
patients is three times higher than that in the CSF of
neurological control subjects (Kotake et al. 1995).
Chronic treatment with 1BnTIQ produces parkinsonian-
like symptoms in rodents and primates (Kotake et al.
1995, 2003; Kohta et al. 2010). Evidence demonstrates
that 1BnTIQ induces cell death via apoptosis and dose-
dependently elevates the level of the pro-apoptotic pro-
tein Bax, while decreasing the concentration of the anti-
apoptotic protein Bcl-xl. Additionally, 1BnTIQ produces
an increase in the formation of the active caspase-3
protein fragments (Shavali and Ebadi 2003). 1BnTIQ,
which is synthesized endogenously in the brain and/or is
obtained exogenously in the diet, can be taken up by
neurons via dopamine transporter (DAT) (Okada et al.
1998). As such, 1BnTIQ accumulates in dopaminergic
neurons, where it is thought to exert some pathological
effects leading to Parkinsonism. In previous studies, we
showed that 1BnTIQ significantly affects dopamine
(DA) structures, producing an increase in the rate of DA
metabolism together with pronounced activation of the
oxidative MAO-dependent catabolic pathway (Ant-
kiewicz-Michaluk et al. 2001; Wa˛sik et al. 2009).
1BnTIQ also significantly inhibits the COMT-dependent
O-methylation pathway. The depression of DA levels
produced by 1BnTIQ is most pronounced in the striatum
and nucleus accumbens because this effect is specific to
dopaminergic neurons.
The aim of this study was to determine the conse-
quences of acute and chronic administrations of 1BnTIQ
on the effects of L-DOPA in the rat brain using behavioral
and biochemical assays. We used the dose of L-DOPA
which produces light stimulation with simultaneously
significant biochemical changes. In neurochemical
experiments, we investigated L-DOPA-induced changes in
the rate of DA metabolism, as well as in vivo DA release
in different brain structures after treatment with 1BnTIQ.
The effects of 1BnTIQ on L-DOPA metabolism in the
striatum and L-DOPA-induced elevation of caspase-3
activity in the hippocampus were also examined. In
behavioral studies, we measured the effects of acute and




All experiments were carried out in male Wistar rats with
an initial body weight of 220–240 g. All animals had free
access to standard laboratory food and tap water and were
kept at room temperature (22 C) under an artificial light/
dark cycle (12/12 h, light on at 7:00).
1-Benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ) was
administered at a dose of 25 or 50 mg/kg intraperitoneally
(i.p.) once or chronically for 14 consecutive days. In the
mixed group, L-DOPA (100 mg/kg i.p.) was administered
once, 15 min after the last 1BnTIQ administration. Control
rats were treated with the appropriate vehicle. Rats were
killed by decapitation 2 h after last drug injections and
different brain structures were dissected for analysis. The
experiments were carried out between 9:00 and 16:00.
All experimental procedures were carried out in accor-
dance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were granted an
approval from the Bioethics Commission as compliant with
Polish Law. All experimental procedures were approved by
the Local Bioethics Commission of the Institute of Phar-
macology, Polish Academy of Sciences in Krako´w.
Drugs
1-Benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ hydro-
chloride) was synthesized (according to Cannon and
Webster 1957) at the Department of Drug Chemistry of the
Institute of Pharmacology, the Polish Academy of Sciences
in Krakow. Purity of the compound was verified by mea-
surement of the melting point and homogeneity was
assessed on a chromatographic column. L-DOPA (Sigma-
Aldrich, USA) was obtained commercially. The com-
pounds were dissolved in a 0.9 % NaCl solution.
Behavioral Study
Locomotor Activity
Locomotor activity was assessed in actometers (Opto-
Varimex activity monitors; Columbus Inst., USA) linked
on-line to a compatible IBM PC. Each cage
(43 9 44 9 25 cm) perimeter was lined with an array of
15 9 15 photocell beams located 3 cm from the floor
surface as reported previously (Filip et al. 2007). Inter-
ruptions of the photocell beams were counted as a measure
of horizontal locomotor activity and were defined as the
distance traveled (in cm). Horizontal locomotor activity
was recorded for 60 (acute treatment group) or 90 min
(14-day chronic treatment group) and analyzed using the
Neurotox Res (2014) 26:240–254 241
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Auto-Track Software Program (Columbus Instruments,
USA). Animals were placed into the actometers for a 15-min
adaptation period before drug administration and behavioral
testing. Rats were given 25 or 50 mg/kg 1BnTIQ i.p. either
as their only acute dose (acute treatment group) or as their
last dose (14-day chronic treatment group). L-DOPA
(100 mg/kg i.p.) was given acutely 15 min after 1BnTIQ
administration. Each group consisted of five to six animals.
Biochemical Studies
Ex Vivo Experiments
DA Metabolism and L-DOPA Metabolism Two hours
after the last 1BnTIQ injection, rats were killed by
decapitation, and the substantia nigra and striatum were
immediately dissected. The tissue was frozen on dry ice
(-70 C) until use in a biochemical assay. The levels of
DA and its metabolites, 3,4-dihydroxyphenylacetic acid
(DOPAC), 3-methoxytyramine (3-MT), and homova-
nillic acid (HVA), as well as the L-DOPA metabolite,
3-methoxy-DOPA (3-MDOPA) were assayed by high-
performance liquid chromatography (HPLC) with electro-
chemical detection (Hewlett Packard 1049A). The tissue
samples were weighed and homogenized in ice-cold 0.1 M
perchloroacetic acid containing 0.05 mM ascorbic acid.
After centrifugation (10,0009g for 5 min), the superna-
tants were filtered through RC 58 0.2-im cellulose mem-
branes (Bioanalytical Systems, West Lafayette, IN, USA).
The HP 1050 chromatograph (Hewlett-Packard, Golden,
CO, USA) was equipped with C18 columns. The electro-
chemical cell potential was 800 mV. The mobile phase
consisted of 0.05 M citrate–phosphate buffer (pH 3.5),
0.1 mM EDTA, 1 mM sodium octyl sulfonate, and 3.5 %
methanol. The flow rate was maintained at 1 ml/min. DA
and its metabolites were quantified by chromatograph peak
height in comparison with standards run on the day of
analysis. Each group consisted of five to six animals.
Assessment of Caspase-3 Activity Caspase-3 activity was
determined according to Nicholson et al. (1995). 1BnTIQ
was administered chronically at a concentration of 25 or
50 mg/kg i.p. for 14 consecutive days. In the mixed group,
L-DOPA (100 mg/kg i.p.) was given once, 15 min after last
1BnTIQ administration. Rats were decapitated 3 h after the
last injection. The assessment of caspase-3 activity was
performed as previously described (Kajta et al. 2009). Cell
lysates were incubated at 36 C with a colorimetric sub-
strate, Ac-DEVD-pNA (N-acetyl-asp-glu-val-asp-p-nitro-
anilide), which is preferentially cleaved by caspase-3. The
absorbance of Ac-DEVD-pNA was monitored continu-
ously over 60 min with a Multiskan Spectrum Microplate
Spectrophotometer (ThermoLabsystems, Vantaa, Finland).
Data were analyzed with Ascent software, normalized to
the absorbance in vehicle-treated cells, and expressed as
the percent of control ± SEM of three to four independent
experiments. The absorbance of blanks, acting as no-
enzyme controls, was subtracted from each value.
In Vivo Microdialysis
Rats were anesthetized with ketamine (75 mg/kg) and
xylazine (10 mg/kg) and secured in a stereotaxic frame
(Stoelting, USA). Vertical microdialysis guide cannulas
(Intracerebral Guide Cannula with stylet; BAS Bioanalyt-
ical, USA) were implanted into the striatum (STR)
according to the following stereotaxic coordinates: A/P
?1.0, L/M ?2.5, and V/D –3.5 mm from bregma and dura
(G. Paxinos and C. H. Watson). 7 days after surgery,
microdialysis probes were inserted into the cannulas, and
the striatum was perfused with an artificial cerebrospinal
fluid (aCSF) consisting of 140 mM NaCl, 2.7 mM KCl,
1.2 mM CaCl2, 1 mM MgCl2, 0.3 mM NaH2PO4, and
1.7 mM Na2HPO4 (pH 7.4) at a flow rate of 1.5 ll/min with
a microinfusion pump (Stoelting, IL, USA). Samples were
collected from freely moving rats in 20-min intervals after
a 3-h wash-out period. 1BnTIQ was injected (acute or
chronic: for 14 consecutive days) in a 50 mg/kg i.p. and
dialysis samples were collected for 180 min. In the mixed
groups, L-DOPA (100 mg/kg i.p.) was administered 40 min
after the last 1BnTIQ injection. All dialysates were
immediately frozen on dry ice (-70 C) until use in a
biochemical assay.
Levels of DA and its extraneuronal metabolite, 3-MT,
were assayed in dialysates (20 ll) using HPLC with elec-
trochemical detection as described above.
Chromatographic data were processed using the Chem-
Station computer program (Hewlett Packard, USA). DA
and its metabolites were quantified by chromatograph peak
height in comparison with standards run on the day of
analysis. At the end of the experiment, frozen brains were
examined histologically for correct probe placement. Each
group consisted of six animals.
Calculations and Statistics
A two-way analysis of variance (ANOVA) for repeated
measures was used to analyze the results of the behavioral
test (locomotor activity). Differences between control and
experimental groups were assessed with Duncan’s post hoc
test. Data from the microdialysis study (acute 1BnTIQ
treatment) were analyzed by a one-way ANOVA for
repeated measures. The results from experiments evaluat-
ing chronic 1BnTIQ administration were analyzed by a
two-way ANOVA for repeated measures, followed by (if
significant differences arose) Duncan’s post hoc test.
242 Neurotox Res (2014) 26:240–254
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The results of the biochemical experiments were ana-
lyzed by a two-way ANOVA, followed, when appropriate,
by Duncan’s post hoc test. The total catabolism rate of
DA was calculated from the ratio of the concentration of
the final DA metabolite, HVA, to the concentration of DA
and was expressed as a catabolism rate index ([HVA]/
[DA] 9 100), as previously described in detail (Ant-
kiewicz-Michaluk et al. 2001). These indices were cal-
culated using the concentrations of individual tissue
samples (n = 6).
Results
Behavioral Study
The Effect of Acute 1BnTIQ Administration on L-DOPA-
Induced Hyperactivity in Rats
L-DOPA (100 mg/kg i.p.) produced a significant increase
in the horizontal locomotor activity of rats (P \ 0.05) from
40 to 60 min. In the same time frame, 1BnTIQ given alone
(25 mg/kg i.p.) did not change locomotor activity (Fig. 1a).
In the mixed group, 1BnTIQ completely antagonized
L-DOPA-induced hyperactivity.
Similarly, acute administration of 1BnTIQ at a higher
dose of 50 mg/kg i.p. did not change locomotor activity,
but completely antagonized L-DOPA-induced hyperactivity
(Fig. 1b).
The Effect of Chronic 1BnTIQ Administration on L-DOPA-
Induced Hyperactivity in Rats
The chronic (14-day) administration of 1BnTIQ at a low
dose of 25 mg/kg i.p. reduced (P \ 0.05) locomotor
activity only during the first 10 min of measurement
(Fig. 2a). L-DOPA (100 mg/kg i.p.) produced a significant
increase in horizontal locomotor activity (P \ 0.01) from
30 to 70 min. In the mixed group, 1BnTIQ completely
antagonized L-DOPA-induced hyperactivity.
Chronic 1BnTIQ administration at a higher dose of
50 mg/kg i.p. did not alter locomotor activity. The increase
in locomotor activity observed with L-DOPA administra-
tion (100 mg/kg i.p.) was completely antagonized by co-
administration of 50 mg/kg 1BnTIQ following chronic
treatment (Fig. 2b).
Fig. 1 The effect of acute
administration of 1BnTIQ on L-
DOPA-induced hyperactivity in
rats. Rats were placed into
actometers and received
treatments after 15 min of
adaptation. Rats received a
single injection of saline
(control), 1BnTIQ [25 mg/kg
i.p. (a) or 50 mg/kg i.p. (b)] or
L-DOPA (100 mg/kg i.p.). In
the mixed group, L-DOPA was
injected 15 min after 1BnTIQ
administration. Movements
were recorded for 60 min. The
data are expressed as the
mean ± SEM (n = 5–6
animals). Data were analyzed
with a two-way ANOVA for
repeated measures, followed by
Duncan’s post-hoc test.
Statistical significance:
*P \ 0.05, **P \ 0.01 versus
saline-treated group; ?P \ 0.05
versus L-DOPA-treated group
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Biochemical Studies: Ex Vivo Experiments
The Effect of Acute 1BnTIQ Administration on L-DOPA-
Induced Changes on DA Metabolism in Rat Brain
Structures
Substantia Nigra A two-way ANOVA indicated a sig-
nificant effect of acute treatment with 1BnTIQ
(F[2,29] = 10.8, P \ 0.01) and L-DOPA (F[2,29] = 10.7,
P \ 0.01) on the DA concentration in the substantia nigra
(Table 1). An interaction between 1BnTIQ and L-DOPA
treatment was also significant (F[2,29] = 8.55, P \ 0.01).
Duncan’s post hoc analysis demonstrated that administra-
tion of L-DOPA strongly increased the level of DA
(approximately 800 %; P \ 0.01). In contrast, both con-
centrations of 1BnTIQ produced reductions in DA con-
centration. 1BnTIQ co-administered with L-DOPA
completely antagonized L-DOPA-induced increases in DA
(the DA level remained just below the control level)
(Table 1).
A two-way ANOVA demonstrated a significant effect of
1BnTIQ (F[2,29] = 13.5, P \ 0.01), as well as L-DOPA
(F[2,29] = 16.5, P \ 0.01) on the concentration of
DOPAC in the substantia nigra (Table 1). An interaction
between 1BnTIQ and L-DOPA was also significant
(F[2,29] = 13.4, P \ 0.01). The post hoc analysis indi-
cated that acute administration of L-DOPA produced
massive elevation of DOPAC concentration (approxi-
mately 10,000 %; P \ 0.01), and this effect was strongly
blocked by both concentrations of 1BnTIQ (Table 1).
The statistical analysis showed a significant effect of
1BnTIQ (F[2,29] = 19.3, P \ 0.01) and L-DOPA
(F[2,29] = 28.9, P \ 0.01) treatment on the levels of
3-MT, as well as an interaction between 1BnTIQ and
L-DOPA (F[2,29] = 10.1, P \ 0.01) (Table 1). Duncan’s
post hoc test showed that L-DOPA induced an increase in
Fig. 2 The influence of chronic administration of 1BnTIQ on L-
DOPA-induced hyperactivity in rats. The influence of chronic
administration of 1BnTIQ on L-DOPA-induced hyperactivity in rats.
The rats were placed into actometers and after 15 min. adaptation
received drugs: 1BnTIQ was administered at two doses [25 mg/kg i.p.
(a) and 50 mg/kg i.p (b) chronic during 14 consecutive days]. In the
mixed group, L-DOPA (100 mg/kg i.p.) was given once, 15 min after
last 1BnTIQ administration. The rats received a single injection of
saline (control). Next the measurement was recorded during 90 min.
The data are mean ± SEM, the number of animals was n = 5–6; The
data were analyzed by means of two-way ANOVA for repeated
measures, followed when appropriate, by Duncan’s post-hoc test.
Statistical significance: *P \ 0.05, **P \ 0.01 versus control group;
?P \ 0.05 versus L-DOPA—treated group
244 Neurotox Res (2014) 26:240–254
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the concentration of 3-MT (approximately 300 %,
P \ 0.01); 1BnTIQ completely antagonized this effect
(Table 1).
Treatment with 1BnTIQ (F[2,29] = 18.7, P \ 0.01) and
L-DOPA (F[2,29] = 45.6, P \ 0.01) had a significant
effect on the HVA concentration in the substantia nigra
(Table 1). This analysis also revealed a significant inter-
action between 1BnTIQ and L-DOPA (F[2,29] = 18.4,
P \ 0.01). The post hoc analysis showed that L-DOPA
administration strongly increased the level of HVA
(approx. 4,000 %, P \ 0.01), and this effect was weakened
by both concentrations of 1BnTIQ (Table 1).
L-DOPA (F[2,29] = 14.8, P \ 0.01) also had a signifi-
cant effect on the rate of DA metabolism, measured as
[HAV]/[DA] (Table 1). The statistical analysis revealed no
effect of 1BnTIQ on the rate of DA metabolism
(F[2,29] = 0.1, N.S.) or interaction between 1BnTIQ and
L-DOPA (F[2,29] = 0.1, N.S.). Duncan’s post hoc analysis
demonstrated that acute doses of L-DOPA strongly
increased the rate of DA metabolism (approximately
800 %; P \ 0.01), and a similar effect was observed when
1BnTIQ (50 mg/kg) was given in combination with
L-DOPA.
Striatum
In the striatum, a two-way ANOVA indicated a significant
effect of both 1BnTIQ (F[2,29] = 26.7, P \ 0.01) and
L-DOPA (F[2,29] = 16.0, P \ 0.01) treatments on the DA
concentration (Table 1). An interaction between 1BnTIQ
and L-DOPA was also revealed by the analysis
(F[2,29] = 15.2, P \ 0.01). Duncan’s post hoc test
showed that acute dose of L-DOPA increased the DA
concentration (approx. 300 %, P \ 0.01). Both concen-
trations of 1BnTIQ completely antagonized this effect
(Table 1).
Table 1 The effects of acute administration of 1BnTIQ on L-DOPA-induced changes in DA metabolism in rat brain structures
Treatment acute Treatment acute DA (ng/g tissue) DOPAC (ng/g tissue) 3-MT (ng/g tissue) HVA (ng/g tissue) HVA/DA
Substantia Nigra
Saline Saline 938 ± 100 216 ± 17 45 ± 4 111 ± 10 12 ± 1
Saline L-DOPA 100 7438 ± 2071** 20649 ± 5208** 162 ± 25** 4701 ± 695** 93 ± 36*
1BnTIQ 25 Saline 534 ± 67?? 147 ± 10?? 24 ± 4?? 91 ± 5?? 18 ± 2
1BnTIQ 50 Saline 566 ± 47?? 171 ± 27?? 27 ± 4?? 101 ± 15?? 18 ± 2
1BnTIQ 25 L-DOPA 100 869 ± 108?? 873 ± 273?? 54 ± 13?? 755 ± 300?? 88 ± 33
1BnTIQ 50 L-DOPA 100 774 ± 93?? 1013 ± 493?? 44 ± 6?? 935 ± 466?? 108 ± 40*































Saline Saline 8691 ± 265 1098 ± 43 380 ± 7 713 ± 26 8.2 ± 0.3
Saline L-DOPA 100 25191 ± 3967** 23040 ± 6005** 281 ± 26** 6238 ± 944** 28.1 ± 7.9*
1BnTIQ 25 Saline 6976 ± 389?? 1428 ± 132?? 348 ± 25? 1065 ± 176?? 15.3 ± 2.4
1BnTIQ 50 Saline 5246 ± 411?? 1187 ± 86?? 271 ± 8** 907 ± 137?? 18.2 ± 3.7
1BnTIQ 25 L-DOPA 100 6669 ± 389?? 2021 ± 373?? 284 ± 12** 1865 ± 414?? 28 ± 5.6*
1BnTIQ 50 L-DOPA 100 5945 ± 646?? 2330 ± 641?? 252 ± 17** 2469 ± 755*?? 41.8 ± 10.5**






























1BnTIQ was acutely administered at two concentrations (25 and 50 mg/kg i.p.). In the mixed group, L-DOPA (100 mg/kg i.p.) was given once,
15 min after 1BnTIQ administration. Rats were decapitated 2 h after the injections. The results are expressed as the mean ± SEM (n = 5–6
animals per group). Data were analyzed with a two-way ANOVA followed by Duncan’s post hoc test. Statistical significance: * P \ 0.05, **
P \ 0.01 versus saline-treated group; ? P \ 0.05, ?? P \ 0.01 versus L-DOPA-treated group
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The statistical analysis showed a significant effect of
1BnTIQ (F[2,29] = 11.1, P \ 0.01) and L-DOPA
(F[2,29] = 14.3, P \ 0.01) treatments on DOPAC levels,
as well as an interaction between 1BnTIQ and L-DOPA
(F[2,29] = 11.5, P \ 0.01) (Table 1). The post hoc ana-
lysis demonstrated that treatment with L-DOPA induced a
massive increase in the level of DOPAC (approximately
2,000 %). This L-DOPA-induced effect was completely
blocked by 1BnTIQ administration (Table 1).
A two-way ANOVA further revealed a significant
effect of acute administration of 1BnTIQ (F[2,29] = 8.5,
P \ 0.01) or L-DOPA (F[2,29] = 17.4, P \ 0.01) on
3-MT concentration in the striatum (Table 1). However, no
interaction between 1BnTIQ and L-DOPA was detected in
this case (F[2,29] = 2.5, N.S.). Duncan’s post hoc test
showed that an acute dose of L-DOPA or 1BnTIQ (50
mg/kg) reduced the levels of 3-MT (approximately 30 %).
A similar effect was observed in the mixed groups.
The statistical analysis indicated a significant effect
of 1BnTIQ (F[2,29] = 8.5, P \ 0.01) and L-DOPA
(F[2,29] = 35.8, P \ 0.01) treatments on HVA levels, as
well as an interaction between 1BnTIQ and L-DOPA
(F[2,29] = 11.2, P \ 0.01). The post hoc analysis showed
that treatment with L-DOPA induced a strong elevation in
the level of HVA (approximately 900 %). This effect was
partially antagonized by 1BnTIQ administration (Table 1).
L-DOPA also had a significant effect (F[2,29] = 13.8,
P \ 0.01) on the rate of DA metabolism measured as
[HAV]/[DA] (Table 1). The statistical analysis revealed no
effect of 1BnTIQ on the rate of DA metabolism
(F[2,29] = 2.0, N.S.) or interaction between 1BnTIQ and
L-DOPA (F[2,29] = 0.4, N.S.). Duncan’s post hoc analysis
demonstrated that acute administration of L-DOPA
increased the rate of DA metabolism (approximately
350 %; P \ 0.05); the strongest effect was observed when
1BnTIQ (50 mg/kg) was administered concomitantly with
L-DOPA (approximately 500 %) (Table 1).
The effect of chronic administration of 1BnTIQ on
L-DOPA-induced changes on DA metabolism in rat brain
structures.
Substantia Nigra
In the substantia nigra, a two-way ANOVA revealed no
effect of chronic treatment with 1BnTIQ (F[2,30] = 2.08,
N.S.) on the DA concentration (Table 2). The statistical
analysis indicated a significant effect of treatment with
L-DOPA (F[2,30] = 12.64, P \ 0.01) on the level of DA.
There was no significant interaction between the chronic
administration of 1BnTIQ and the acute dose of L-DOPA
(F[2,30] = 2.00, N.S.). Duncan’s post hoc test showed that
the acute administration of L-DOPA produced an increase
in the DA concentration (approximately 1,000 %;
P \ 0.01). Additionally, when 1BnTIQ (50 mg/kg) given
chronically was coupled with an acute dose of L-DOPA, a
significant increase in the level of DA was observed
(approx. 700 %; P \ 0.05) (Table 2).
A two-way ANOVA demonstrated a significant effect
of chronic treatment with 1BnTIQ (F[2,30] = 8.99,
P \ 0.01), as well as acute L-DOPA administration
(F[2,30] = 25.72, P \ 0.01) on the DOPAC concentration
in the substantia nigra (Table 2). An interaction between
1BnTIQ and L-DOPA was also detected (F[2,30] = 8.94,
P \ 0.01). The post hoc analysis showed that L-DOPA
produced a massive increase in the DOPAC concentration
(approximately 10,000 %; P \ 0.01); this effect was par-
tially blocked by chronic treatment with 1BnTIQ (Table 2).
The statistical analysis revealed no effect of chronic
treatment with 1BnTIQ (F[2,30] = 2.22, N.S.) on the
level of 3-MT (Table 2). Treatment with L-DOPA
(F[2,30] = 34.2, P \ 0.01) significantly affected the 3-MT
concentration. There was no interaction between chronic
administration of 1BnTIQ and acute administration of
L-DOPA (F[2,30] = 2.55, N.S.). Duncan’s post hoc test
showed that acute doses of L-DOPA produced an increase
in 3-MT concentration (approximately 500 %; P \ 0.01).
When 1BnTIQ (50 mg/kg) given chronically was coupled
with an acute dose of L-DOPA, a significant elevation in
the levels of 3-MT (approx. 400 %; P \ 0.01) was also
observed (Table 2).
A two-way ANOVA demonstrated a significant effect
of chronic treatment with 1BnTIQ (F[2,30] = 5.92,
P \ 0.01), as well as acute L-DOPA administration
(F[2,30] = 55.78, P \ 0.01) on the HVA concentration in
the substantia nigra (Table 2). An interaction between
1BnTIQ and L-DOPA was also detected (F[2,30] = 5.92,
P \ 0.01). The post hoc analysis showed that L-DOPA
produced a massive increase in the HVA concentration
(approximately 8,000 %; P \ 0.01); this effect was par-
tially blocked by chronic treatment with both concentra-
tions of 1BnTIQ (Table 2).
L-DOPA significantly (F[2,30] = 14.8, P \ 0.01)
affected the rate of DA metabolism measured as [HVA]/
[DA] (Table 2). The statistical analysis revealed no effect
of chronic administration of 1BnTIQ on the rate of DA
metabolism (F[2,30] = 0.1, N.S.) or interaction between
1BnTIQ and L-DOPA (F[2,30] = 0.1, N.S.). Duncan’s post
hoc analysis demonstrated that acute treatment with
L-DOPA strongly increased the rate of DA metabolism
(approximately 800 %; P \ 0.01); a similar effect was
observed in the mixed groups when 1BnTIQ (25 and
50 mg/kg) was coupled with acute L-DOPA (Table 2).
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Striatum
In the striatum, a two-way ANOVA revealed no effect of
chronic treatment with 1BnTIQ (F[2,30] = 2.94, N.S.) on the
DA concentration (Table 2). In contrast, the acute L-DOPA
treatment produced a significant effect on the level of DA
(F[2,30] = 25.54, P \ 0.01). The statistical analysis
revealed no interaction between chronic administration of
1BnTIQ and L-DOPA administration (F[2,30] = 1.13, N.S.).
The post hoc test indicated that acute doses of L-DOPA
increased the level of DA (approximately 300 %, P \ 0.01)
and that this effect was antagonized only by chronic treatment
with a lower (25 mg/kg) concentration of 1BnTIQ (Table 2).
A two-way ANOVA demonstrated a significant effect of
chronic treatment with 1BnTIQ (F[2,30] = 23.8,
P \ 0.01) as well as the acute administration of L-DOPA
(F[2,30] = 36.4, P \ 0.01) on the DOPAC concentration
in rat striatum (Table 2). An interaction between 1BnTIQ
and L-DOPA was also detected (F[2,30] = 23.2,
P \ 0.01). The post hoc analysis showed that L-DOPA
produced a massive increase in DOPAC concentration
(approximately 2,000 %; P \ 0.01); this effect was com-
pletely blocked by chronic treatment with both concen-
trations of 1BnTIQ (Table 2).
Chronic administration of 1BnTIQ (F[2,30] = 4.18,
P\0.05) and acute administration of L-DOPA
(F[2,30] = 23.67, P\0.01) both significantly affected the
3-MT concentration in striatum (Table 2). The statistical ana-
lysis also revealed an interaction between 1BnTIQ and L-DOPA
(F[2,30] = 7.16, P\0.01). Duncan’s post hoc test showed
that L-DOPA decreased the level of 3-MT (approximately
30 %; P\0.01) and this effect was reversed by chronic
treatment with both concentrations of 1BnTIQ (Table 2).
A two-way ANOVA revealed a significant effect of both
the chronic 1BnTIQ treatment (F[2,30] = 5.75, P \ 0.01)
and acute L-DOPA administration (F[2,30] = 66.71,
Table 2 The effects of chronic administration of 1BnTIQ on L-DOPA-induced changes in DA metabolism in rat brain structures
Treatment chronic Treatment acute DA (ng/g tissue) DOPAC (ng/g tissue) 3-MT (ng/g tissue) HVA (ng/g tissue) HVA/DA
Substantia nigra
Saline Saline 564 ± 44 206 ± 39 37 ± 2 84 ± 9 15 ± 2
Saline L-DOPA 100 5556 ± 1015** 25178 ± 5309** 181 ± 24** 6410 ± 641** 129 ± 16**
1BnTIQ 25 Saline 502 ± 23?? 174 ± 11?? 40 ± 3?? 83 ± 7?? 17 ± 2
1BnTIQ 50 Saline 413 ± 16?? 180 ± 16?? 32 ± 2?? 99 ± 8?? 24 ± 2
1BnTIQ 25 L-DOPA 100 1272 ± 180? 2210 ± 628?? 89 ± 11?? 1864 ± 514?? 128 ± 30**
1BnTIQ 50 L-DOPA 100 3987 ± 2414* 8142 ± 4355?? 142 ± 45** 4080 ± 1394**? 181 ± 30**































Saline Saline 9793 ± 426 1486 ± 122 383 ± 16 701 ± 34 7.2 ± 0.3
Saline L-DOPA 100 25128 ± 2755** 33727 ± 6080** 269 ± 16** 9696 ± 870** 39.5 ± 2.4**
1BnTIQ 25 Saline 7645 ± 525?? 1142 ± 84?? 410 ± 21?? 735 ± 57?? 9.9 ± 1.1??
1BnTIQ 50 Saline 6042 ± 348? 1415 ± 147?? 335 ± 14?? 1111 ± 104?? 18.6 ± 1.8**??
1BnTIQ 25 L-DOPA 100 14653 ± 3192?? 4283 ± 922?? 330 ± 15*? 3634 ± 769*?? 25.1 ± 4.6**??
1BnTIQ 50 L-DOPA 100 18281 ± 5335** 3318 ± 550?? 338 ± 13?? 7452 ± 1903** 42.6 ± 2.3**






























1BnTIQ was chronic administered at two concentrations (25 and 50 mg/kg i.p.) during 14 consecutive days. In the mixed group, L-DOPA
(100 mg/kg i.p.) was given once, 15 min after last 1BnTIQ administration. Rats were decapitated 2 h after the injections. The results are
expressed as the mean ± SEM of six samples (n = 6 animals per group). Data were analyzed with a two-way ANOVA followed by Duncan’s
post hoc test. Statistical significance: * P \ 0.05, ** P \ 0.01 versus saline group; ? P \ 0.05, ?? P \ 0.01 versus L-DOPA group
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P \ 0.01) on the HVA concentration in the striatum
(Table 2). An interaction between the chronic administra-
tion of 1BnTIQ and L-DOPA was also detected
(F[2,30] = 5.62, P \ 0.01). The post hoc analysis dem-
onstrated that L-DOPA strongly increased the HVA con-
centration (approximately 1,400 %; P \ 0.01); this effect
was partially antagonized only by chronic treatment with a
lower (25 mg/kg) concentration of 1BnTIQ (Table 2).
Chronic administration with 1BnTIQ (F[2,30] = 14.0,
P \ 0.01) and acute L-DOPA administration (F[2,30] =
138, P \ 0.01) produced significant effects on the rate of
DA metabolism measured as [HAV]/[DA] (Table 2). An
interaction between 1BnTIQ and L-DOPA was also sig-
nificant (F[2,30] = 5.9, P \ 0.01). Duncan’s post hoc
analysis demonstrated that chronic treatment with a higher
(50 mg/kg) concentration of 1BnTIQ and acute adminis-
tration of L-DOPA induced an increase the rate of DA
metabolism (approximately 300 and 600 %, respectively).
Only a lower dose (25 mg/kg) of 1BnTIQ given chroni-
cally could partially antagonize this effect (Table 2).
The Effect of Acute and Chronic Administration of 1BnTIQ
on L-DOPA Metabolism in Rat Striatum
A two-way ANOVA demonstrated a significant effect of
acute treatment with 1BnTIQ (F[1,18] = 7.38, P \ 0.05)
or L-DOPA (F[1,18] = 26.7, P \ 0.01) on the 3-MDOPA
concentration in striatum (Table 3). An interaction between
1BnTIQ and L-DOPA was also detected (F[1,18] = 7.38,
P \ 0.05). Duncan’s post hoc test indicated that L-DOPA
produced a massive increase the level of 3-MDOPA (by
approx. 30,000 times; P \ 0.01); this effect was strongly
blocked (by approximately 70 %; P \ 0.01) by acute
treatment with 1BnTIQ (50 mg/kg i.p.). Similarly, a two-
way ANOVA revealed a significant effect of chronic
administration of 1BnTIQ (F[2,30] = 6.18, P \ 0.01) and
acute administration of L-DOPA (F[2,30] = 69.8,
P \ 0.01) on the concentration of 3-MDOPA in the stria-
tum. Here again, the interaction between 1BnTIQ and
L-DOPA was significant (F[2,30] = 6.19, P \ 0.01). The
post hoc analysis demonstrated that L-DOPA strongly
increased the 3-MDOPA concentration (P \ 0.01); this
effect was strongly inhibited by chronic treatment with a
lower (25 mg/kg) concentration of 1BnTIQ (Table 3),
while the higher concentration of 1BnTIQ (50 mg/kg)
antagonized this effect only partially (P \ 0.05) (Table 3).
The Effect of Chronic Administration of 1BnTIQ on the
L-DOPA-Induced Elevation of Caspase-3 Activity in Rat
Hippocampus
Chronic systemic administration of 1BnTIQ at a concentration
of 25 mg/kg did not alter caspase-3 activity in the hippocam-
pus, whereas a higher concentration of 1BnTIQ (50 mg/kg)
produced only a slight increase in this activity (Fig. 3). As
expected, acute administration of L-DOPA (100 mg/kg i.p.)
induced a significant increase (approx. 100 %; P \ 0.01) in the
activity of caspase-3 in the hippocampus. This effect was
completely inhibited by multiple injections of 1BnTIQ at both
concentrations (P \ 0.01) (Fig. 3).
In Vivo Microdialysis
The Effects of a Single Administration of 1BnTIQ on
L-DOPA-Induced Changes in DA Release in Rat Striatum
A repeated one-way ANOVA revealed no effect of treat-
ment on DA release into the extracellular space after acute
Table 3 The impact of acute and chronic administration of 1BnTIQ
on L-DOPA-induced increase the concentration of 3-MDOPA in rat
striatum
Treatment acute Treatment acute 3-MDOPA (ng/g tissue)
Saline Saline 1.5 ± 0.19
Saline L-DOPA 100 48687 ± 8801**
1BnTIQ 50 Saline 1.43 ± 0.17
1BnTIQ 50 L-DOPA 100 15125 ± 3468??
Effect of 1BnTIQ F(1/18) = 7.38
P \ 0.05
Effect of L-DOPA F(1/18) = 26.7
P \ 0.01
Interaction of 1BnTIQ ? L-DOPA F(1/18) = 7.38
P \ 0.05
Treatmentchronic Treatmentacute 3-MDOPA(ng/g tissue)
Saline Saline 1.49 ± 0.22
Saline L-DOPA 100 26868 ± 3867**
1BnTIQ 25 Saline 1.52 ± 0.24
1BnTIQ 50 Saline 1.17 ± 0.12
1BnTIQ 25 L-DOPA 100 8381 ± 1714??
1BnTIQ 50 L-DOPA 100 18635 ± 4868**?
Effect of 1BnTIQ F(2/30) = 6.18
P \ 0.01
Effect of L-DOPA F(2/30) = 69.78
P \ 0.01
Interaction of 1BnTIQ ? L-DOPA F(2/30) = 6.19
P \ 0.01
1BnTIQ was administered acute or chronic during 14 consecutive
days at two concentrations (25 and 50 mg/kg i.p.). In the mixed
group, L-DOPA (100 mg/kg i.p.) was given once, 15 min after
1BnTIQ administration. Rats were decapitated 2 h after the injec-
tions. The results are expressed as the mean ± SEM (n = 5–6 ani-
mals per group). Data were analyzed with a two-way ANOVA
followed by Duncan’s post hoc test. Statistical significance: *
P \ 0.05, ** P \ 0.01 versus saline group; ? P \ 0.05, ?? P \ 0.01
versus L-DOPA group
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administration of either 1BnTIQ (50 mg/kg i.p.) or
L-DOPA (100 mg/kg i.p.) (F[2,12] = 3.03, N.S.). How-
ever, an effect of time (F[12,144] = 4.14, P \ 0.01) and
an interaction between time and treatment were detected
(F[24,144] = 2.99, P \ 0.01). Duncan’s post hoc analysis
showed that acute L-DOPA administration produced a
significant (P \ 0.01) and long-lasting increase in DA
release in the rat striatum (by approximately 500 %)
Fig. 3 The effect of 1BnTIQ on L-DOPA-induced increase in
caspase-3 activity in rat hippocampus. 1BnTIQ was administered
chronically at concentrations of 25 or 50 mg/kg i.p. for 14 consec-
utive days. In the mixed group, L-DOPA (100 mg/kg i.p.) was given
once, 30 min after last 1BnTIQ administration. Rats were decapitated
3 h after the last injection. The results are expressed as the
mean ± SEM (n = 6 animals per group). Data were analyzed with
a two-way ANOVA, followed by Duncan’s post hoc test. Statistical
significance: **P \ 0.01 versus saline-treated group; ##P \ 0.01
versus L-DOPA-treated group
Fig. 4 The effects of acute
administration of 1BnTIQ on
L-DOPA-induced changes in
DA release (a) and 3-MT
concentration (b) in rat striatum.
Control samples were collected
from ‘‘–60’’ to ‘‘0;’’ then,
1BnTIQ (50 mg/kg; at
timepoint ‘‘0’’) or L-DOPA
(100 mg/kg; at timepoint ‘‘40’’)
was administered i.p. Dialysates
were collected every 20 min. In
the mixed group, 1BnTIQ was
injected 40 min before L-DOPA
administration. The
concentration of DA (a) and its
extraneuronal metabolite 3-MT
(b) was measured. The basal
level of DA in striatum was
10.6 ± 3.1 pg/20 ll. The data
are expressed as the
mean ± SEM (n = 5–6).
Statistical significance:
*P \ 0.05, **P \ 0.01 from the
basal value (Duncan’s test)
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(Fig. 4a). 1BnTIQ alone did not produce a change in DA
release. The post hoc test indicated that 1BnTIQ combined
with L-DOPA potentiated the effect of L-DOPA and pro-
duced a long-lasting increase in the release of DA (up to
1,300 %) (P \ 0.01) in the striatum (Fig. 4a).
A repeated one-way ANOVA did not reveal any effect
of treatment on the concentration of 3-MT after a single
injection of 1BnTIQ (50 mg/kg i.p.) or L-DOPA (100
mg/kg i.p.) (F[2,12] = 1.15, N.S.). As for DA, an effect of
time (F[12,144] = 2.09, P \ 0.05) was detected, but the
interaction between time and treatment was not significant
(F[24,144] = 0.98, N.S.). Duncan’s test indicated that
acute L-DOPA administration produced a significant
(P \ 0.05) increase in the concentration of 3-MT in the rat
striatum (up to 250 %) (Fig. 4b).
The Effects of Multiple Administrations of 1BnTIQ on L-
DOPA-Induced Changes in DA Release in Rat Striatum
A repeated two-way ANOVA showed a significant effect
of chronic administration of 1BnTIQ (50 mg/kg i.p.)
(F[1,18] = 15.56, P \ 0.01) on DA release (treatment 1),
but the effect of acute dose of L-DOPA (treatment 2) was not
significant (100 mg/kg i.p.) (F[1,18] = 3.1, N.S.). No
interaction between treatment 1 and treatment 2 was found
(F[1,18] = 0.27, N.S.) (Fig. 4a). The statistical analysis
demonstrated a significant effect of time (F[12,216] = 4.36,
P \ 0.01), as well as an interaction between time and
treatment 2 (F[12,216] = 5.24, P \ 0.01). However, there
was no interaction between time and treatment 1
(F[12,216] = 0.81, N.S.) or between time, treatment 1, and
treatment 2 (F[12,216] = 0.23, N.S.). Duncan’s post hoc
test indicated that acute L-DOPA administration produced a
significant (P \ 0.01) and long-lasting increase in DA
release in the striatum (up to 500 %) (Fig. 5a).
A repeated two-way ANOVA showed that chronic
administration of 1BnTIQ increased the release of DA in
the rat striatum by up to 300 % and, after the last dose,
release of DA was elevated by an additional 100 %
(Fig. 5a). In the mixed group, chronic administration of
1BnTIQ weakened the effects of L-DOPA when compared
to the group treated with L-DOPA alone (Fig. 5a).
Fig. 5 The effects of and
chronic administration of
1BnTIQ on L-DOPA-induced
changes in DA release (a) and
3-MT concentration (b) in rat
striatum. 1BnTIQ was
administered chronic at dose
50 mg/kg i.p. during 14
consecutive days. In the mixed
group, L-DOPA (100 mg/kg
i.p.) was given once, 40 min
after last 1BnTIQ
administration. The control
group was treated with saline.
The dialysate was collected
every 20 min. The concentration
of DA (a) and its extraneuronal
metabolite 3-MT (b) was
measured. The data are
expressed as the mean ± SEM
(n = 5–6). Statistical
significance: *P \ 0.05,
**P \ 0.01 from the basal
value; ?P \ 0.05 versus
L-DOPA—treated group
(Duncan’s test)
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A repeated two-way ANOVA found no significant effect
of treatment 1 after chronic administration of 1BnTIQ
(50 mg/kg i.p.) (F[1,18] = 0.66, N.S.) or of treatment 2
after an acute dose of L-DOPA (100 mg/kg i.p.) on the
concentration of 3-MT (F[1,18] = 2.21, N.S.). Further-
more, there was no interaction between treatment 1 and
treatment 2 (F[1,18] = 1.41, N.S.) (Fig. 5b). The statistical
analysis showed no significant effect of time
(F[12,216] = 0.57, N.S.), time versus treatment 1
(F[12,216] = 0.96, N.S.), or time versus treatment 1 versus
treatment 2 (F[12,216] = 1.42, N.S.). However, there was
a significant interaction between time and treatment 2
(F[12,216] = 1.98, P \ 0.05). Duncan’s post hoc analysis
showed that acute L-DOPA administration produced a
significant (P \ 0.05) elevation in the concentration of
3-MT (up to 250 %); this effect was completely antago-
nized by chronic administration of 1BnTIQ (Fig. 5b).
Discussion
The main finding of this study was that both acute and
chronic systemic administrations of the endogenous neu-
rotoxin 1BnTIQ disturbed the behavioral and biochemical
effects of L-DOPA in the rat. Biochemical ex vivo studies
have shown that administration of L-DOPA (100 mg/kg
i.p.), as a precursor of DA, causes a significant increase in
DA metabolism, its concentration, and the concentration of
all DA metabolites in the extrapyramidal brain structures
substantia nigra and striatum. 1BnTIQ, at both investigated
concentrations (25 and 50 mg/kg), completely antagonized
the effect of L-DOPA in the rat brain. Comparing the
results of our behavioral test and our ex vivo and in vivo
biochemical experiments, we observed that 1BnTIQ does
not always act in the same direction. In the behavioral and
ex vivo experiments, 1BnTIQ completely antagonized the
L-DOPA-induced biochemical effects, while the in vivo
microdialysis studies demonstrated the potentiation by
1BnTIQ of L-DOPA-evoked DA release in the striatum
(specifically after acute administration of 1BnTIQ;
Fig. 4a). Additionally, we have found that chronic
administration of 1BnTIQ completely blocks the L-DOPA-
induced increase in caspase-3 activity in the hippocampus.
DA was discovered as a neurotransmitter in the animal
brain based on its specific regional distribution. 1BnTIQ,
like reserpine, a specific inhibitor of vesicular monoamine
uptake transporter (VMAT2), produces depletion of striatal
DA, such that even synthesized DA is not stored in vesicles
efficiently (Wa˛sik et al. 2009). Reserpine is a model sub-
stance frequently used to produce parkinsonism in animals
(Colpaert 1987; Lorenc-Koci et al. 1995). Dysfunction of
DA neurons has been explicitly correlated with damage to
basic transport and storage mechanisms of
neurotransmitters [neuronal (DAT) and vesicular
(VMAT2) uptake]. The above findings suggest that
1BnTIQ may damage the VMAT2 in dopaminergic neu-
rons, leading to the pathological release of DA into the
cytosol. L-DOPA therapy supplements DA deficiencies and
increases its metabolism in the brain. Peripheral co-
administration of aromatic L-amino acid decarboxylase
(AADC) inhibitors (carbidopa, benserazid) improves the
bioavailability of L-DOPA (Bartholini et al. 1967). Exog-
enously administered L-DOPA may be taken up into DA
terminals in the brain by the DA reuptake transporter DAT
and may be decarboxylated to DA, primarily within
AADC-containing cells in the striatum. Therefore, the
undisturbed function of DAT is a crucial factor for
increasing DA metabolism and the therapeutic effective-
ness of L-DOPA in the clinic. Our previous studies, carried
out in rat striatum slices, demonstrated that 1BnTIQ sig-
nificantly inhibits (IC50 in low micromolar concentrations)
the DA reuptake transporter (Patsenka et al. 2004). A
similar effect was shown by Okada et al. (1998), where
1BnTIQ inhibited the uptake of [3H]dopamine through the
DAT expressed in HEK293 cells. In light of these findings,
DAT is a likely candidate responsible for the selective
transport of 1BnTIQ into dopaminergic neurons, leading to
the 1BnTIQ neurotoxicity correlated with impairment of
DA storage by inhibition of VMAT2 (Wa˛sik et al. 2009).
Our biochemical ex vivo studies showed that adminis-
tration of L-DOPA (100 mg/kg i.p.) causes an increase in
DA and all its metabolites (DOPAC, 3-MT, and HVA) both
in the substantia nigra and in the striatum (Table 1).
1BnTIQ at both concentrations (25 and 50 mg/kg i.p.)
decreased DA in the nigrostriatal structures (Table 1). In
the mixed groups, L-DOPA-induced effects were com-
pletely inhibited by both single and multiple administra-
tions of 1BnTIQ. The differences between acute and
chronic administration that we observed suggest that,
during chronic administration of 1BnTIQ, some tolerance
to its DA-depressing effect develops, while the impairment
of DA synthesis continues. On the other hand, weakening
in the inhibitory action 1BnTIQ after repeated adminis-
tration may indicate adaptation in the brain and/or brain
plasticity. Our ex vivo studies suggest that 1BnTIQ pre-
vents the uptake of L-DOPA into the neuron and/or blocks
the conversion of L-DOPA into DA. As mentioned,
1BnTIQ antagonism of L-DOPA-evoked increase in DA
metabolism could be linked to DAT inhibition by 1BnTIQ
(Okada et al. 1998; Patsenka et al. 2004). In fact, the
in vivo microdialysis results discussed in this paper support
this hypothesis. Our results show that 1BnTIQ alone
(50 mg/kg i.p.) does not produce significant changes in DA
release (Fig. 4a). However Katagiri et al. (2009) reported
that acute 1BnTIQ (40 mg/kg i.p.) injection produced a
weak increase in the DA release. The discrepancies
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between our results may be explained through the different
areas of the cannula implantation. While our dialysates
were collected from central part of the striatum (Fig. 6); in
the case of Katagiri et al. (2009) it was done from part of
the ventral striatum.
L-DOPA is a direct substrate for COMT, and its
metabolism leads to the production of 3-O-methyl-dopa
(3-MDOPA) in the brain. Therefore, COMT is responsible
both for the metabolic inactivation of extraneuronal DA to
3-MT and for the metabolism of L-DOPA to 3-MDOPA
(Kopin 1985; Antkiewicz-Michaluk et al. 2001). Selective
COMT inhibitors, such as entacapone, tolcapone, and
CGP28014, effectively block the O-methylation of
L-DOPA and the formation of 3-MDOPA, thus improving
its bioavailability and brain penetration (Kaakkola et al.
1994). COMT inhibitors are used as an adjunctive treat-
ment for PD as they increase central L-DOPA availability
(Mannisto and Kaakkola 1999). Our ex vivo and in vivo
studies clearly support the notion that 1BnTIQ inhibits
COMT-activity, as it significantly decreased the concen-
trations of both the L-DOPA and DA metabolites,
3-MDOPA and 3-MT, respectively (Table 3; Figs. 4b, 5b).
1BnTIQ given acutely 40 min before L-DOPA (100
mg/kg i.p.) administration, augmented L-DOPA effect and
was produced an additional increase in the extraneuronal
DA concentration (up to 1,300 %; P \ 0.01) in striatum
(Fig. 4a). However, chronic administration of 1BnTIQ
clearly weakens this increase in the L-DOPA effect, likely
as a result of the tolerance development (Fig. 5a). The
effect of 1BnTIQ connected with the COMT inhibition
presented in the paper and discussed above can explained
the potentiation of L-DOPA-produced an increase of the
extraneuronal DA concentration in microdialysis study
(Figs. 4a, 5a).
It is well known that although L-DOPA is the gold
standard for the treatment of PD symptoms. L-DOPA can
lead to adverse effects, either as a result of oxidative stress
because it has the potential to auto-oxidize to a quinine
derivative, generating ROS and depleting striatal GSH
(Ogawa et al. 1994; Spencer et al. 1996; Hattoria et al.
2009), or by inducing apoptosis, as evidenced by the
increased activity of caspase-3 and DNA damage via a
mechanism independent of oxidative stress (Pedrosa and
Soares-da-Silva 2002; Tanaka and Ogawa 2005; Emdadul
Haque et al. 2003). We confirmed these findings with one
of our ex vivo experiments: acute L-DOPA injection pro-
duced a significant increase in caspase-3 activity, an effect
that was completely inhibited by chronic administration of
1BnTIQ at both tested concentrations (Fig. 3). It appears
that we are observing artificial ‘‘neuroprotective’’ effects of
1BnTIQ, related to its inhibition of DAT activity, and thus
of L-DOPA neuronal uptake.
We know from our previous in vitro study that 1BnTIQ,
at micromolar concentrations, has neurotoxic activity in rat
hippocampal cultures, in which it increases apoptotic
markers (caspase-3 activity and LDH release; Wa˛sik et al.
2014). However, follow-up ex vivo studies suggested that
chronic administration of 1BnTIQ did not have neurotoxic
effects on dopaminergic neurons in the substantia nigra, as
assessed by tyrosine hydroxylase activity and the level of
alpha-synuclein (Wa˛sik et al. 2014). In contrast, in vitro
experiments carried out in human dopaminergic cells
showed that 1BnTIQ increased alpha-synuclein expression
and caused nuclear damage (Shavali et al. 2004).
The results obtained from our behavioral studies are in
agreement with the results of the biochemical ex vivo
analysis in demonstrating both acute and chronic 1BnTIQ
antagonisms of L-DOPA-induced locomotor hyperactivity
in rat (Figs. 1a, b, 2a, b). However, in the combined
groups, stereotyped behaviors linked to L-DOPA adminis-
trations, such as sniffing and sometimes licking were still
present.
In conclusion, our results demonstrate that 1BnTIQ is
not only an endogenous neurotoxin that disrupts the
activity of dopaminergic neurons but is also an antagonist
of L-DOPA-evoked behavioral and biochemical effects.
The data from our ex vivo biochemical analysis and in vivo
microdialysis study suggest that the molecular mechanism
of action of 1BnTIQ may involve its inhibition of either or
both DAT and COMT activities in the brain. Furthermore,
elevated endogenous levels of 1BnTIQ may cause serious
adverse effects in PD patients undergoing of L-DOPA
therapy.
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